辅助化疗对FIGO I期高级别浆液性卵巢癌患者生存的影响
基于荷兰2002至2014年223例FIGO I期高级别浆液性卵巢癌且接受手术分期患者的队列研究显示,辅助化疗组复发21/101例(21%),未化疗组46/122例(38%),多变量HR 0.37(95%CI 0.22-0.64,p<0.01);5年无复发生存率分别为81%和59%。中位随访105个月,化疗组死亡21例(21%),未化疗组38例(31%),多变量HR 0.50(95%CI 0.28-0.89,p=0.02);10年总生存率分别为78%和62%。结论认为辅助化疗改善长期无复发生存和总生存。
要点
- 辅助化疗组复发21/101例(21%),未化疗组46/122例(38%),多变量HR 0.37(95%CI 0.22-0.64,p<0.01)。
- 5年无复发生存率化疗组81%,未化疗组59%。
- 中位随访105个月,化疗组死亡21/101例(21%),未化疗组38/122例(31%),多变量HR 0.50(95%CI 0.28-0.89,p=0.02);10年总生存率分别为78%和62%。
核心结论
- 辅助化疗改善FIGO I期高级别浆液性卵巢癌患者 optimal staging 后的长期无复发生存和总生存。
研究设计与样本
- 基于人群的队列研究,纳入2002至2014年荷兰诊断为FIGO I期高级别浆液性卵巢癌且接受手术分期的患者,共223例。
- 数据来自荷兰癌症登记处和荷兰病理登记处,复发数据来自医院病历。
- 采用Kaplan-Meier法估计无复发生存和总生存,Cox比例风险分析控制基线特征差异。
主要发现
- 复发事件:化疗组21/101例(21%),未化疗组46/122例(38%),多变量HR 0.37(95%CI 0.22-0.64,p<0.01)。
- 5年无复发生存率:化疗组81%,未化疗组59%。
- 中位随访105个月,死亡:化疗组21/101例(21%),未化疗组38/122例(31%),多变量HR 0.50(95%CI 0.28-0.89,p=0.02)。
- 10年总生存率:化疗组78%,未化疗组62%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The benefit of adjuvant chemotherapy for FIGO stage I, high-grade serous ovarian cancer (HGSOC) after optimal staging is a matter of debate. We investigated the effect of adjuvant chemotherapy on recurrence-free survival (RFS) and overall survival (OS) in a population-based cohort study. METHODS: All patients diagnosed in the Netherlands between 2002 and 2014 with FIGO stage I HGSOC who underwent surgical staging were included. Data on clinical characteristics, histopathology, completeness of staging and survival were collected from the Netherlands Cancer Registry and Dutch Pathology Registry. Recurrence data was collected from hospital files. We used Kaplan-Meier methods to estimate RFS and OS and Cox-proportional hazard analyses to control for differences in baseline characteristics between patients who did or did not receive chemotherapy. RESULTS: We identified 223 patients who underwent optimal staging procedures including lymph node sampling. Events of disease recurrence occurred in 21 of the 101 patients (21%) who received adjuvant chemotherapy and in 46 of the 122 patients (38%) who did not (multivariable hazard ratio (HR), 0.37; 95%CI 0.22-0.64; p < 0.01). Five-year RFS was 81% after staging plus chemotherapy and 59% after staging only. At a median follow-up of 105 months, 21 patients (21%) in the chemotherapy group and 38 patients (31%) in the no-chemotherapy group had died (multivariable HR 0.50; 95%CI 0.28-0.89; p = 0.02). Ten-year OS was 78% with chemotherapy and 62% without chemotherapy. CONCLUSIONS: Adjuvant chemotherapy improves long-term RFS and OS in patients with FIGO stage I HGSOC after optimal staging.
引用
- van Baal JOAM, Van de Vijver KK, Algera MD, et al. The effect of adjuvant chemotherapy on survival in patients with FIGO stage I high-grade serous ovarian cancer. Gynecol Oncol. 2019. PMID: 30948193. doi:10.1016/j.ygyno.2019.03.257
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。